Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling

Breast Cancer Research and Treatment
Lisa Goto-YamaguchiHirotaka Iwase

Abstract

Neoadjuvant endocrine therapy (NAET) for estrogen receptor-positive primary breast cancer causes adequate tumor shrinkage, and is expected to be helpful for breast-conserving surgery, but the adaptation criteria, especially in regard to treatment duration, have never been elucidated. Re-visiting past gene expression profiles, we explored the data for specialized pre-therapeutic predictors and validated the results using our in-house clinical cohorts. We sorted the genes related to a > 30% tumor volume reduction through NAET from a cDNA microarray data-set of GSE20181, then selected the top 40 genes. We validated these gene expression levels using pre-therapeutic biopsy samples obtained from patients treated with long-term NAET (over 4 months; N = 40). A short-term (2-8 weeks; N = 37) NAET cohort was also validated to clarify whether expression of these genes is also related to a rapid response of Ki67 and PEPI score. In the long-term group, higher expression of KRAS, CUL2, FAM13A, ADCK2, and LILRA2 was significantly associated with tumor shrinkage, and KRAS, MMS19, and IVD were related to lower PEPI score (≤ 3). Meanwhile in the short-term group, none of these genes except CUL2 showed a direct correlation with Ki67 reduction or...Continue Reading

References

Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettIan E Smith
Sep 7, 2007·Breast Cancer Research and Treatment·Yutaka YamamotoHirotaka Iwase
Dec 7, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Delphine J LeeRobert L Modlin
Jun 24, 2008·Nature Reviews. Molecular Cell Biology·Antoine E Karnoub, Robert A Weinberg
Sep 24, 2008·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Hirotaka Iwase
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniele GeneraliStephen B Fox
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Oct 1, 2011·Journal of the National Cancer Institute·Mitch DowsettUNKNOWN International Ki-67 in Breast Cancer Working Group
Oct 11, 2011·Cancer Discovery·Rachel BroughAlan Ashworth
Nov 2, 2011·Journal of the National Cancer Institute. Monographs·Mitch DowsettJudith Bliss
Dec 6, 2011·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Mutsuko IbusukiHirotaka Iwase
Oct 8, 2013·Journal of Translational Medicine·Maddalena MarchesiGiuseppe V Masucci
Jun 28, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Duveken B Y FonteinCornelis J H van de Velde
Apr 25, 2015·Nature Reviews. Cancer·Cynthia X MaMatthew J Ellis
Feb 11, 2016·American Journal of Respiratory and Critical Care Medicine·Zhiqiang JiangXiaobo Zhou
May 13, 2017·Cancer Discovery·Angel L Guerrero-Zotano, Carlos L Arteaga
Jan 25, 2018·Oncogenesis·Varvara PetrovaIvano Amelio

❮ Previous
Next ❯

Citations

Jun 20, 2019·Current Molecular Medicine·Ying WeiXinhan Zhao
Aug 20, 2019·World Journal of Clinical Cases·Li-Tong YaoYing-Ying Xu
Jun 3, 2021·Cancers·Covadonga Martí, José Ignacio Sánchez-Méndez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.